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Summary
Background Postinfectious cough is common in primary care, but has no proven eﬀ ective treatments. Cysteinyl 
leukotrienes are involved in the pathogenesis of postinfectious cough and whooping cough (pertussis). We investigated 
the eﬀ ectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatment of postinfectious cough.
Methods In this randomised, placebo-controlled trial, non-smoking adults aged 16–49 years with postinfectious 
cough of 2–8 weeks’ duration were recruited from 25 general practices in England. Patients were tested for pertussis 
(oral ﬂ uid anti-pertussis toxin IgG) and randomly assigned (1:1) to montelukast 10 mg daily or image-matched placebo 
for 2 weeks. Patients chose whether to continue study drug for another 2 weeks. The randomisation sequence was 
computer-generated and stratiﬁ ed by general practice. Patients, health-care professionals, and researchers were 
masked to treatment allocation. Eﬀ ectiveness was assessed with the Leicester Cough Questionnaire to measure 
changes in cough-speciﬁ c quality of life; the primary outcomes were changes in total score between baseline and two 
follow-up stages (2 weeks and 4 weeks). The primary analysis was by intention to treat with imputation by last 
observation carried forward. Recruitment closed on Sept 21, 2012, and follow-up has been completed. This trial is 
registered with EudraCT (2010-019647-19), UKCRN Portfolio (ID 8360), and ClinicalTrials.gov (NCT01279668).
Findings From April 13, 2011, to Sept 21, 2012, we randomly assigned 276 patients to montelukast (n=137) or placebo 
(n=139). 70 (25%) patients had laboratory-conﬁ rmed pertussis. Improvements in cough-speciﬁ c quality of life 
occurred in both groups after 2 weeks (montelukast: mean 2·7, 95% CI 2·2–3·3; placebo: 3·6, 2·9–4·3), but the 
diﬀ erence between groups did not meet the minimum clinically important diﬀ erence of 1·3 (mean diﬀ erence –0·9, 
–1·7 to –0·04, p=0·04). This diﬀ erence was not statistically signiﬁ cant in any sensitivity analyses. After 2 weeks, 
192 of 259 participants from whom data were available elected to continue study drug (99 [77%] of 129 participants on 
montelukast; 93 [72%] of 130 on placebo). After 4 weeks, there were no signiﬁ cant between-group diﬀ erences in 
cough-speciﬁ c quality of life improvement (montelukast: 5·2, 4·5–5·9; placebo: 5·9, 5·1–6·7; mean diﬀ erence –0·5, 
–1·5 to 0·6, p=0·38) or adverse event rates (21 (15%) of 137 patients on montelukast reported one or more adverse 
events; 31 (22%) of 139 on placebo; p=0·14). The most common adverse events reported were increased mucus 
production (montelukast, n=6; placebo, n=2), gastrointestinal disturbance (montelukast, n=3; placebo, n=5), and 
headache (montelukast, n=2; placebo, n=6). One serious adverse event was reported (placebo, n=1), which was 
unrelated to study drug (shortness of breath and throat tightness after severe coughing bouts).
Interpretation Montelukast is not an eﬀ ective treatment for postinfectious cough. However, the burden of 
postinfectious cough in primary care is high, making it an ideal setting for future antitussive treatment trials.
Funding National Institute for Health Research School for Primary Care Research, UK.
Introduction
Postinfectious cough is commonly encountered in 
primary care and can aﬀ ect nearly 40% of adults after an 
acute respiratory tract infection.1 Postinfectious coughs 
present as subacute coughs and are thought to be caused 
by airway inﬂ ammation, epithelial disruption, and hyper-
responsiveness.2 Cysteinyl leukotrienes are likely to be 
important in postinfectious cough. In non-atopic adults, 
infection with rhinovirus increases expression of 
5-lipoxygenase and 5-lipoxygenase-activating protein, 
which are both involved in the production of cysteinyl 
leukotrienes.3 Increased cysteinyl leukotriene con-
centrations are reported in the nasal secretions of adults 
infected with respiratory syncytial virus (RSV), 
rhinovirus, or inﬂ uenza A virus4 and in the lung tissues 
of mice5 and rats6 infected with RSV. Raised 
concentrations are also observed in children with RSV 
bronchiolitis7 and virus-induced wheeze.8 Cysteinyl 
leukotrienes promote virus-induced airway inﬂ ammation 
by activating pulmonary dendritic cells5 and potentiating 
the eﬀ ects of inﬂ ammatory neuropeptides.6 Respiratory 
viruses can also sensitise airways to leukotrienes by 
increasing production of interferon-γ,8 thereby increasing 
cysteinyl leukotriene type 1 receptor expression.9
The expression of cysteinyl leukotriene type 1 receptors 
can also be upregulated by T helper cell type 2 (Th2)-type 
cytokines.10 In adults, rhinovirus infection activates both 
Th1 and Th2-like cytokine responses. The balance 
between these responses might help to determine clinical 
outcome. Strong Th2-like cytokine responses are 
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associated with increased symptom severity and increased 
time to virus clearance from sputum.11 These factors 
might be important in the pathogenesis of persistent 
virus-induced symptoms including postinfectious cough. 
Th1 cells have also been shown to increase Th2 cell-
mediated airway inﬂ ammation in the mouse 
model.12 Additionally, infection with whooping cough 
(pertussis), which is recognised to be an important cause 
of postinfectious cough,13 is associated with increased 
production of the Th2-like cytokine interleukin-13 in the 
mouse model.14 Interleukin-13 is known to upregulate 
cysteinyl leukotriene production and receptor expression.15
Montelukast is a cysteinyl leukotriene type 1 receptor 
antagonist that is reported to improve cough16 and 
prevent exercise-induced bronchoconstriction17 in 
asthma. A trial comparing montelukast with ketotifen in 
the treatment of postinfectious cough18 had inconclusive 
ﬁ ndings due to the use of poorly deﬁ ned outcome 
measures, including subjective clinical eﬃ  cacy ratings 
and an unvalidated four-point cough score. In another 
trial, montelukast was associated with signiﬁ cantly 
greater resolution of post-RSV bronchiolitis symptoms 
(cough, wheeze, shortness of breath) compared with 
placebo.19 However, this ﬁ nding was based on a post-hoc 
analysis of participants retrospectively deﬁ ned as having 
persistent symptoms (ie, mean percentage of symptom-
free days 30% or less during the ﬁ rst 2 weeks of 
treatment). A systematic review of treatments for 
pertussis-induced cough did not identify any trials of 
leukotriene receptor antagonists.20
We aimed to establish the eﬀ ectiveness of montelukast 
in the treatment of postinfectious cough and explore in a 
subgroup analysis the eﬃ  cacy of montelukast in the 
treatment of pertussis-induced cough.
Methods
Participants
For this randomised, placebo-controlled trial, health-care 
professionals at 25 general practices in the Thames 
Valley and southwest England recruited patients aged 
16–49 years with postinfectious cough. Postinfectious 
cough was deﬁ ned as cough of 2–8 weeks’ duration 
triggered by an acute respiratory tract infection or with 
no established diagnosis (since the initial infection can 
cause very mild or no symptoms). Health-care pro-
fessionals screened patients’ eligibility for trial parti-
cipation. Exclusion criteria were contraindication to 
montelukast, chronic severe disease associated with 
cough (eg, cystic ﬁ brosis, bronchiectasis, cardiac failure), 
known immunodeﬁ ciency or immunocompromise, 
current smoker or recent ex-smoker (ie, gave up smoking 
less than 6 months ago), pregnancy, breastfeeding, 
regular treatment known to be associated with causing 
cough (eg, angiotensin-converting enzyme inhibitors), 
and participation in another clinical research study. 
Written informed consent was obtained from each 
participant. The trial was approved by Southampton and 
South West Hampshire Research Ethics Committee 
(10/H0502/37).
Randomisation and masking
Patients were randomly assigned to receive montelukast 
sodium 10 mg tablets or image-matched placebo tablets 
(main excipient lactose monohydrate; Merck, Sharp & 
Dohme, West Point, PA, USA) with a 1:1 allocation within 
each general practice. The randomisation sequence was 
computer-generated and retained by an independent 
statistician and stratiﬁ ed by general practice with a ﬁ xed 
block size of four. Participants, health-care professionals, 
and research staﬀ  were masked to treatment allocation, 
since montelukast and placebo tablets and bottles were 
identical in appearance.
Procedures
On study entry (day 0), health-care professionals recorded 
participants’ date of birth, sex, duration of cough, self-
administered drugs for cough, and household smoking 
status. Participants were also asked if they had experienced 
wheeze or nasal symptoms (sneezing, blocked nose, runny 
nose, itchy nose) since their cough started. Each participant 
was asked to rate how bothersome their nasal symptoms 
had been on a 100 mm visual analogue scale (VAS; 0=not 
at all bothersome, 100=extremely bothersome). An oral 
ﬂ uid sample was obtained from each participant and 
tested at the Health Protection Agency (London, UK; now 
Public Health England). Laboratory-conﬁ rmed pertussis 
was deﬁ ned as an oral ﬂ uid anti-pertussis toxin IgG titre of 
70 arbitrary units or more.21
Participants received study drugs in a bottle containing 
28 montelukast 10 mg or placebo tablets. All participants 
were asked to take one tablet daily from days 1–14 and 
avoid taking self-administered treatment for cough. After 
2 weeks, participants chose whether to continue their 
study drug.
At baseline, 2 weeks, and 4 weeks, participants were 
asked to complete the Leicester Cough Questionnaire 
(LCQ). The range of possible LCQ total scores is from 
3 to 21, with a higher score indicating a better cough-
speciﬁ c quality of life.22 Additionally, participants were 
asked to rate on a seven-point Likert scale how often 
during the past 2 weeks their cough got worse with 
exercise (1=every time I exercise, 7=never). Participants 
were also asked to record daily cough severity on a 
100 mm cough VAS (days 0–14), number of paroxysms of 
cough (days 0–14), and study drug intake (days 1–14).
Health-care professionals recorded data for adverse 
events and cessation of cough at 2 weeks and 4 weeks. 
Data were extracted from participants’ medical records 
on pertussis vaccinations, medical conditions, previous 
interventions, and further interventions for the cough 
(consultations, prescribed drugs, and investigations) up 
to 4 weeks after study entry.
The primary outcomes were LCQ total score changes 
between baseline and two follow-up points (2 weeks and 
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4 weeks). Changes in LCQ physical, psychological, and 
social domain scores between baseline and both follow-
up points were secondary outcomes. Other secondary 
outcomes were overall cough severity, paroxysmal cough 
severity, cessation of cough, cessation of exercise-induced 
cough, further interventions for cough, and adverse 
events. We measured overall cough severity and 
paroxysmal cough severity by calculating areas under the 
curve (AUC) from days 1–14 for cough VAS scores and 
number of paroxysms of cough, respectively. Cessation 
of exercise-induced cough was deﬁ ned as a score of 
6 (rarely) or 7 (never).
Study drug adherence was deﬁ ned as taking at least 
50% of tablets, because plasma concentrations of 
montelukast in healthy adults have been shown to reach 
and maintain a steady state by day 2 of a 7-day treatment 
course (montelukast 10 mg daily)23 and all trial 
participants were asked to take a minimum of 14 tablets 
of study drug. Furthermore, on the basis of clinical 
experience, we judged that any treatment eﬀ ect would be 
most pronounced during the ﬁ rst week, when cough was 
most severe.
Statistical analysis
Allowing for a 25% dropout rate, our target sample size 
was 288 participants, giving an eﬀ ective sample size of 
216 participants. This number would give more than 
80% power to detect the minimum clinically important 
diﬀ erence in LCQ total score change (1·3), assuming a 
SD of 3·3 and two-tailed α of 0·05. The minimum 
clinically important diﬀ erence is the smallest change in 
LCQ score which patients perceive to be clinically 
signiﬁ cant.24
We analysed data using STATA version 12SE. We did 
not do an interim analysis. We summarised continuous 
baseline characteristics of all randomly assigned 
participants using means and SDs (parametric data) or 
medians and IQRs (non-parametric data). We 
summarised categorical variables using numbers and 
percentages. We estimated overall recruitment rate and 
prevalence of laboratory-conﬁ rmed pertussis with 
95% CIs and calculated attrition rates in each group.
Primary outcome and LCQ domain score data were 
analysed by intention to treat with imputation by last 
observation carried forward as speciﬁ ed in our statistical 
analysis plan. This imputation method is recommended 
as a conservative approach in cases where the condition 
is expected to improve spontaneously over time.25 We 
calculated mean changes in LCQ total scores with 
95% CIs using analysis of covariance (ANCOVA) 
adjusted for baseline scores and other baseline covariates 
(age, sex, atopy, pertussis status, pertussis vaccination 
status, duration of cough, paroxysmal cough severity, and 
exercise-induced cough severity). Baseline data for 
paroxysmal cough severity were obtained from 
participants’ responses to LCQ item 11 (frequency of 
coughing bouts).
Per-protocol analyses were done for our primary 
outcomes in trial participants who met study eligibility 
criteria, showed study drug adherence, reported taking 
no self-administered drugs for cough and completed 
baseline and both follow-up Leicester Cough 
Questionnaires. Prespeciﬁ ed sensitivity analyses 
involved complete case analysis, adjustment for multiple 
comparisons (using α=0·025), multiple imputation to 
impute missing LCQ total and domain scores (univariate, 
linear regression with ﬁ ve datasets), mean values to 
impute missing baseline data, and best and worst 
possible prognosis in both groups.
Changes in LCQ domain scores, overall cough severity, 
and paroxysmal cough severity were also analysed with 
ANCOVA adjusted for baseline scores and other baseline 
covariates as previously listed. Logistic regression 
analyses adjusted for these same baseline covariates were 
done to assess between-group diﬀ erences in cessation of 
cough and exercise-induced cough after 2 and 4 weeks. 
Proportions of patients who reported adverse events and 
underwent further interventions for cough during the 
4 weeks after study entry were compared with χ² tests. 
We did exploratory analyses of our primary outcomes, 
Figure 1: Trial proﬁ le
LCQ=Leicester Cough Questionnaire (primary outcome measure). *Eight patients were randomised in error, four to 
montelukast (one outside age range; one on angiotensin-converting enzyme inhibitor therapy; one with previous 
splenectomy; and one who gave up smoking less than 6 months ago), and four to placebo (all outside age range); 
number of patients analysed for primary outcome was 136 for montelukast and 139 for placebo (one patient 
assigned to montelukast did not complete the Leicester Cough Questionnaire at baseline). †Did not complete 
Leicester Cough Questionnaire at 2 weeks or 4 weeks and were not withdrawn from the study. ‡Completed 
Leicester Cough Questionnaire at 2 weeks, but not at 4 weeks, and were not withdrawn from the study.
126 (92%) patients in the trial at 2 weeks
118 (86%) completed LCQ at 2 weeks
126 (91%) patients in the trial at 2 weeks
122 (88%) completed LCQ at 2 weeks
111 (81%) patients completed LCQ at 4 weeks
103 (75%) completed LCQs at 2 and 4 weeks
110 (79%) patients completed LCQ at 4 weeks
106 (76%) completed LCQs at 2 and 4 weeks
14 lost to follow-up‡
1 withdrew consent
13 lost to follow-up‡
2 withdrew consent
1 withdrawn by clinician
8 lost to follow-up†
2 withdrew consent
1 withdrawn by clinician
8 lost to follow-up†
3 withdrew consent
2 withdrawn by clinician
137 assigned to montelukast 139 assigned to placebo
276 randomised*
63 excluded
34 not eligible
29 eligible but declined to participate
339 patients assessed for eligibility
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overall cough severity, and paroxysmal cough severity 
adjusted for baseline scores in participants with 
laboratory-conﬁ rmed pertussis.
This trial is registered with EudraCT (2010-019647-19), 
UKCRN Portfolio (ID 8360), and ClinicalTrials.gov 
(NCT01279668).
Role of the funding source
Neither the funding source nor Merck, Sharp & Dohme 
were involved in study design, data collection, analysis or 
interpretation, report writing, or submission for 
publication. KW, KT, and RP had full access to all study 
data. KW had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between April 13, 2011, and Sept 21, 2012, we screened 
339 patients of whom 276 were randomly allocated to 
receive montelukast (n=137) or placebo (n=139). This 
sample size allowed for a 22% dropout rate. 
Figure 1 summarises recruitment and follow-up of 
participants. Eight participants who did not meet trial 
eligibility criteria were randomly assigned to groups in 
error (montelukast, n=4; placebo, n=4). Recruitment 
rate was 90% (268/297 eligible patients, 95% CI 
86·9–93·6) in patients meeting trial eligibility criteria. 
Attrition rates did not diﬀ er signiﬁ cantly between 
groups at 2 weeks (11 [8%] of 137 participants on 
montelukast; 13 [9%] of 139 participants on placebo; 
p=0·70) or 4 weeks (15 [11%] participants on montelukast; 
16 [12%] on placebo; p=0·88).
At 2 weeks, 116 (85%) of 137 participants in the 
montelukast group and 118 (85%) of 139 participants in the 
placebo group adhered to study drug. 192 of 259 patients 
from whom data were available elected to continue study 
drug (montelukast, n=99 of 129; placebo, n=93 of 130). 
61 participants in each group took 14 or more study drug 
tablets. Table 1 summarises the baseline characteristics of 
participants. Both groups reported severe impairment in 
cough-speciﬁ c quality of life based on LCQ total scores. 
70 (25%, 95% CI 20·2–30·5) of 276 participants had 
laboratory-conﬁ rmed pertussis.
Table 2 summarises changes in LCQ total and domain 
scores. Large improvements in cough-speciﬁ c quality of 
life based on LCQ total score changes were reported in 
both groups at 2 weeks (montelukast: mean 2·7, 95% CI 
2·2–3·3; placebo: 3·6, 95% CI 2·9–4·3). The adjusted 
mean between-group diﬀ erence was statistically 
signiﬁ cant (–0·9, 95% CI –1·7 to 0·04, p=0·04), but not 
clinically signiﬁ cant (LCQ minimum clinically important 
diﬀ erence=1·3). Large improvements in cough-speciﬁ c 
quality of life were also reported at 4 weeks (montelukast: 
mean 5·2, 95% CI 4·5–5·9; placebo: mean 5·9, 95% CI 
5·1–6·7), but the adjusted mean between-group 
diﬀ erence was neither clinically nor statistically 
signiﬁ cant (–0·5, 95% CI –1·5 to 0·6, p=0·38). Between-
group diﬀ erences in LCQ total score changes after 2 and 
4 weeks were neither clinically nor statistically signiﬁ cant 
in any per-protocol or sensitivity analyses (appendix).
Improvements in all three LCQ domains were observed 
in both groups at 2 and 4 weeks. At 2 weeks, the adjusted 
mean between-group diﬀ erence in LCQ physical domain 
score change (–0·2, 95% CI –0·5 to 0·01, p=0·04), and 
that in LCQ psychological domain score change (–0·3, 
95% CI –0·6 to –0·01, p=0·03) were both statistically but 
not clinically signiﬁ cant.
Montelukast was associated with lower overall cough 
severity than placebo (mean AUC of daily cough VAS 
scores: montelukast 483·9, 95% CI 439·0–528·9; placebo 
Montelukast 
(n=137)
Placebo 
(n=139)
Age (years) 37·9 (9·6) 37·8 (9·5)
Sex (female) 82 (60%) 97 (70%)
Smoker(s) in household 18 (13%) 15 (11%)
Pertussis* 31 (23%) 39 (28%)
Pertussis vaccination status (three doses)† 52 (38%) 58 (42%)
Atopy‡ 22 (16%) 19 (14%)
Clinical features
Duration of cough (weeks) 5·0 (1·9) 4·8 (1·8)
Duration of cough ≤4 weeks 62 (45%) 70 (50%)
Nasal symptoms§ 102 (74%) 99 (71%)
Nasal symptom severity (VAS score, mm) 49 (19–78) 55 (22–76)
Wheeze 83 (61%) 88 (63%)
Exercise-induced cough severity¶ 3·9 (1·9) 3·4 (1·9)
Previous interventions for current postinfectious cough
≥2 primary care consultations 42 (31%) 53 (38%)
Chest radiograph 13 (9%) 13 (9%)
Antibiotics 45 (33%) 54 (39%)
Self-administered treatment
Dextromethorphan 29 (21%) 31 (22%)
Codeine/pholcodeine 15 (11%) 19 (14%)
Antihistamines 7 (5%) 8 (6%)
Outcome variables
LCQ total score|| 10·8 (3·0) 10·1 (2·8)
LCQ physical domain score|| 3·8 (1·0) 3·6 (1·0)
LCQ psychological domain|| 3·7 (1·1) 3·4 (1·0)
LCQ social domain|| 3·4 (1·2) 3·1 (1·2)
Cough severity, day 0 (VAS score, mm)** 58 (37–72·5) 62 (37–74)
Number of paroxysms of cough, day 0†† 8 (4–20) 9 (5–20)
Data are number (%), mean (SD), or median (IQR). VAS=visual analogue scale 
(100 mm); cough VAS: 0=no cough, 100=worst cough ever; nasal symptom 
severity VAS: 0=not at all bothersome, 100=extremely bothersome. 
LCQ=Leicester Cough Questionnaire; range of possible scores 3–21. *Oral ﬂ uid 
anti-pertussis toxin IgG titre ≥70 arbitrary units. †Number of childhood 
vaccination records available: montelukast, n=84; placebo, n=85. ‡Diagnosis of 
asthma, hay fever, allergic rhinitis, or atopic eczema listed as active problem in 
participant’s medical record. §Itchy nose, runny nose, blocked nose, or sneezing. 
¶Montelukast, n=133; placebo, n=139; participants rated on seven-point Likert 
scale how often their cough got worse when they exercised: 1=every time I 
exercise, 2=most times when I exercise, 3=several times when I exercise, 4=some 
times when I exercise, 5=occasionally when I exercise, 6=rarely, 7=never. 
||Montelukast, n=136; placebo, n=139. **Montelukast, n=120; placebo, n=125. 
††Montelukast, n=117; placebo, n=122.
Table 1: Baseline characteristics 
See Online for appendix
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540·5, 95% CI 487·8–593·1), but the adjusted mean 
between-group diﬀ erence was not statistically signiﬁ cant 
(–23·8, 95% CI –83·5 to 35·9, p=0·44). Montelukast was 
also associated with lower paroxysmal cough severity 
than placebo (mean AUC of daily number of paroxysms 
of cough: montelukast 151·1, 95% CI 107·3–194·9; 
placebo 171·3, 95% CI 131·4–211·2), but the adjusted 
mean between-group diﬀ erence was also not statistically 
signiﬁ cant (15·0, 95% CI –22·0 to 51·9, p=0·43).
The likelihood of cough cessation at 2 and 4 weeks was 
similar in both groups (adjusted odds ratio [OR] 1·0, 
95% CI 0·6–1·8, at both stages). Treatment with 
montelukast also did not signiﬁ cantly improve the 
likelihood of exercise-induced cough cessation at 2 weeks 
(adjusted OR 1·4, 95% CI 0·8–2·8) or 4 weeks (1·4, 
95% CI 0·7–2·6). Similar proportions of participants in 
both groups underwent further interventions for cough 
(25 [18%] of 137 patients on montelukast; 24 [17%] of 
139 on placebo; p=0·83).
Table 3 summarises adverse events. The proportions of 
patients reporting one or more adverse events did not 
diﬀ er signiﬁ cantly between groups (21 [15%] of 
137 participants on montelukast; 31 [22%] of 139 participants 
on placebo; p=0·14). Seven participants reported two 
adverse events (montelukast, n=2; placebo, n=5) and one 
reported four adverse events (placebo, n=1). Only one 
serious adverse event was reported, which was unrelated 
to study drug (placebo, n=1). The participant reported 
shortness of breath and throat tightness after taking one 
tablet of study drug. This event was initially treated as 
an anaphylactic reaction. However, the participant 
subsequently reported having these symptoms after severe 
coughing bouts, even before commencing study drug.
In participants with laboratory-conﬁ rmed pertussis, 
montelukast was associated with lower overall and 
paroxysmal cough severity than placebo (appendix). 
However, the diﬀ erences between groups were of 
uncertain clinical relevance. Diﬀ erences in LCQ total 
score changes between baseline and both follow-up 
stages were neither clinically nor statistically signiﬁ cant.
Having observed large clinical improvements in cough-
speciﬁ c quality of life at 2 weeks, we decided post hoc to 
explore the earlier timecourse of postinfectious cough by 
summarising daily cough VAS scores and numbers of 
paroxysms of cough from days 0–14 (ﬁ gure 2). Rapid, 
immediate improvements in cough VAS scores were 
observed in both groups after starting study drug (day 1). 
Daily numbers of paroxysms of cough remained stable 
until day 3, but subsequently followed a ﬂ uctuating 
course with an overall improving trend.
Discussion
To our knowledge, we report the ﬁ rst double-blind 
randomised placebo-controlled trial of montelukast for 
the treatment of postinfectious cough (panel). Large 
improvements in cough-speciﬁ c quality of life were 
reported in both treatment groups, showing the 
self-limiting nature of postinfectious cough.26,27 However, 
our results show that montelukast is not an eﬀ ective 
treatment for postinfectious cough. Our ﬁ ndings can 
be generalised to most non-smoking young adults with 
postinfectious cough, since our trial was done in 
primary care (where most of these patients present) 
using a pragmatic clinical deﬁ nition of postinfectious 
cough.
Montelukast, 
mean diﬀ erence*
Placebo, mean 
diﬀ erence*
Mean between-
group diﬀ erence† 
(unadjusted)
Mean between-
group diﬀ erence† 
(adjusted)‡
Baseline to 2 weeks
Total§ (MCID=1·3) 2·7 (2·2 to 3·3) 3·6 (2·9 to 4·3) –0·8 (–1·7 to 0·03), 
p=0·06
–0·9 (–1·7 to –0·04), 
p=0·04
Physical (MCID=0·2) 0·8 (0·6 to 0·9) 1·0 (0·8 to 1·2) –0·2 (–0·5 to 0·04), 
p=0·11
–0·2 (–0·5 to 0·01), 
p=0·04
Psychological (MCID=0·8) 0·9 (0·7 to 1·1) 1·3 (1·0 to 1·5) –0·4 (–0·7 to –0·05), 
p=0·02
–0·3 (–0·6 to –0·01), 
p=0·03
Social (MCID=0·2) 1·0 (0·8 to 1·3) 1·3 (1·0 to 1·6) –0·3 (–0·6 to 0·1), 
p=0·14
–0·3 (–0·6 to 0·04), 
p=0·08
Baseline to 4 weeks¶
Total§ (MCID=1·3) 5·2 (4·5 to 5·9) 5·9 (5·1 to 6·7) –0·7 (–1·8 to 0·3), 
p=0·19
–0·5 (–1·5 to 0·6), 
p=0·38
Physical (MCID=0·2) 1·5 (1·3 to 1·8) 1·7 (1·4 to 1·9) –0·1 (–0·5 to 0·2), 
p=0·38
–0·1 (–0·4 to 0·2), 
p=0·46
Psychological (MCID=0·8) 1·7 (1·5 to 2·0) 2·0 (1·8 to 2·3) –0·3 (–0·7 to 0·1), 
p=0·11
–0·1 (–0·5 to 0·2), 
p=0·41
Social (MCID=0·2) 1·9 (1·6 to 2·2) 2·2 (1·9 to 2·5) –0·3 (–0·7 to 0·1), 
p=0·21
–0·2 (–0·6 to 0·2), 
p=0·33
Data are mean diﬀ erence (95% CI), (p value). MCID=minimum clinically important diﬀ erence (ie, smallest change in 
score which patients perceive to be clinically signiﬁ cant). *Positive mean diﬀ erence indicates an improvement in 
cough-speciﬁ c quality of life. †Positive between group diﬀ erence indicates greater improvement in montelukast group 
than in placebo group. ‡Adjustment for baseline scores, age, sex, duration of cough, pertussis status, pertussis 
immunisation status, atopy, paroxysmal cough severity, and exercise-induced cough severity. §Primary outcome. 
¶192 participants elected to continue drug at 2 weeks (montelukast, n=99; placebo, n=93).
Table 2: Changes in Leicester Cough Questionnaire total and domain scores
Montelukast 
(n=22)
Placebo 
(n=39)
Increased mucus production 6 2
Upper respiratory tract infection 4 2
Gastrointestinal disturbance 3 5
Headache 2 6
Skin rash, itching 2 4
Nasal symptoms 1 5
Diﬃ  culty breathing, wheezing 1 2
Dry mouth, increased thirst 1 1
Hoarse voice, dry throat 0 4
Chest or breast discomfort 0 3
Lower respiratory tract infection 0 2
Fainting 0 1
Other* 2 2
n=total number of events. *Montelukast group: hiccups (n=1), cough triggered 
by beauty or hair products (n=1); placebo group: diﬃ  culty sleeping (n=1), 
ankle swelling (n=1).
Table 3: Adverse events
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Postinfectious cough was associated with more severe 
impairment in cough-speciﬁ c quality of life than 
chronic24 or acute cough28 particularly in the LCQ 
psychological domain. This ﬁ nding might have been due 
to concerns about the cough failing to settle as quickly as 
an acute cough and failure to adapt to the cough because 
of its subacute rather than chronic nature. Placebo 
treatments have been associated with antitussive eﬀ ects, 
which might be due to a combination of natural 
resolution, true placebo eﬀ ect, and other factors, 
including patient beliefs about the drug and aspects 
relating to participation in a research study.29 However, 
the placebo eﬀ ect over and above montelukast that we 
recorded in this study is most likely due to chance, 
because it was not shown in any of our sensitivity 
analyses. A quarter of participants had laboratory-
conﬁ rmed pertussis. Although recruitment coincided 
with a national pertussis epidemic, this proportion was 
still similar to that reported by a Canadian study, which 
found laboratory evidence of pertussis in a ﬁ fth of 
adolescents and adults with acute or subacute cough.13
In patients with cough-variant asthma, montelukast 
has previously been associated with signiﬁ cantly 
greater reductions in daily cough frequency than placebo 
after 2 weeks (mean change from baseline 54·1% vs 
15·2%, p<0·001) and 4 weeks (75·7% vs 20·7%, 
p<0·01).16 Furthermore, zaﬁ rlukast, another cysteinyl 
leukotriene receptor antagonist, has been shown to 
suppress cough sensitivity to capsaicin and improve 
patient-reported cough scores.30 Recent observational data 
suggest that the antitussive eﬀ ect of montelukast in 
cough-variant asthma might be mediated by reductions 
in eosinophil production and cough reﬂ ex sensitivity 
rather than by direct cysteinyl leukotriene inhibition, 
although airway hyper-responsiveness at baseline might 
predict a better treatment response.31 However, although 
increased cough reﬂ ex sensitivity1 and airway hyper-
responsiveness32 have been shown in postinfectious 
cough, these patients have lower blood and nasal 
eosinophil counts than patients with asthma and similar 
sputum eosinophil counts to normal patients.32
Pertussis is associated with increased pulmonary 
eosinophil counts5,14 and increased production of and 
prolonged sensitivity to bradykinin, which increases 
responsiveness to cough stimuli.33 Montelukast also 
produces dose-dependent inhibition of bradykinin-
induced tracheal smooth muscle contraction in guinea 
pigs.34 However, we were only able to do an exploratory 
subgroup analysis in trial participants with laboratory-
conﬁ rmed pertussis and were therefore unable to 
establish whether montelukast is an eﬃ  cacious treatment 
for cough in patients with laboratory-conﬁ rmed pertussis.
Improvements in cough severity during the ﬁ rst week 
have been reported in trial participants with 
postinfectious cough.26,27 However, these observations 
were of uncertain clinical signiﬁ cance because they were 
based on unvalidated patient-reported four-point cough 
scores (0=no cough, 3=severe cough). The cough VAS 
score minimum clinically important diﬀ erence is 17 mm 
in acute cough.35 We observed similar magnitudes of 
cough VAS score improvement in both groups at day 4, 
whereas paroxysmal cough initially followed a stable 
course before steadily improving. Prerandomisation 
assessment of cough stability27 would therefore not be 
helpful in patients with postinfectious cough.
Although recruitment of patients with postinfectious 
cough is reported to be diﬃ  cult,27 our high recruitment 
and low attrition rates show that primary care is an ideal 
setting for antitussive treatment trials. Our high 
recruitment rate is likely to have been assisted by the 
severe impairment in cough-speciﬁ c quality of life in our 
target population, the absence of any proven eﬀ ective 
treatments for postinfectious cough, and the inclusion of 
a non-invasive oral ﬂ uid test to diagnose pertussis, which 
is not usually available as part of the routine clinical 
assessment of postinfectious cough. Detection of 
Figure 2: Timecourse of postinfectious cough (days 0–14)
(A) Daily cough visual analogue scale (VAS) scores completed by participants 
(0=no cough, 100=worst cough ever). (B) Daily number of paroxysms of cough 
reported by participants. Data are daily median values and IQRs. Day 0=baseline. 
Participants started taking study drug on day 1.
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anti-pertussis toxin IgG in oral ﬂ uid has 93% sensitivity 
and 94% speciﬁ city compared with serology,21 which is 
positive in less than 1% of the general population.36 We 
achieved low attrition rates by timing contact with health-
care professionals to coincide with when participants 
were required to complete the LCQ.
To ensure our results would be valid and clinically 
relevant, we used the LCQ to measure our primary 
outcomes. Although the LCQ minimum clinically 
important diﬀ erence has not been established for 
postinfectious cough, it is likely to be between those for 
chronic cough (1·3)24 and acute cough (2·5).28 We ensured 
that our trial would have adequate power by calculating 
our sample size using the LCQ minimum clinically 
important diﬀ erence for chronic cough.
Having observed large improvements in cough-speciﬁ c 
quality of life in both groups at 2 weeks, we explored post 
hoc the earlier timecourses of improvements in cough 
VAS score and paroxysmal cough frequency. These have 
not previously been described in postinfectious cough. 
Our observations will therefore be instrumental in 
guiding their use in future trials.
Although one of our speciﬁ ed primary outcomes was 
LCQ total score change between baseline and 4 weeks, 
this outcome was less robust than the LCQ total score 
change between baseline and 2 weeks because around a 
quarter of participants elected to discontinue study drug 
after 2 weeks. Cough monitoring would have been useful 
to measure cough frequency objectively,37 but was not 
possible because of resource constraints. For similarly 
pragmatic reasons, we also assessed exercise-induced 
cough using an unvalidated patient-reported score and 
obtained baseline covariate data on paroxysmal cough 
severity from LCQ item 11, although this item has not 
been validated for use in isolation.
We recruited participants using a clinical deﬁ nition of 
postinfectious cough and restricted recruitment to young 
non-smoking adults because we regarded the risk of 
signiﬁ cant pathology in this population to be low. We did 
not have suﬃ  cient resources to routinely perform chest 
radiographs and other investigations to exclude 
signiﬁ cant pathology before study entry. Furthermore, 
exclusion of smokers from trials of antitussive treatments 
is standard practice because the relationship between 
smoking and cough reﬂ ex sensitivity is complex. 
Although some studies report that cough reﬂ ex sensitivity 
is diminished in smokers,38 others report increased 
bronchial hyper-reactivity associated with smoking.39,40
Although general practice consultation rates for upper 
respiratory tract infections are known to be highest in 
children and young people, and consultation rates for 
lower respiratory tract infections to be highest in adults 
aged 65 years and older,41 the epidemiology of 
postinfectious cough is poorly understood.2 Although 
our trial included participants between 16 and 49 years of 
age for pragmatic reasons, postinfectious cough has 
been shown in children42 and in older adult study 
populations including individuals up to 76 years of 
age.43 Our ﬁ ndings might therefore not be generalisable 
to these age groups. Future antitussive treatment trials 
should aim to include children younger than 16 years of 
age and adults older than 49 years of age and smokers 
with postinfectious cough in whom signiﬁ cant pathology 
has been excluded. To inform the design of future trials, 
further research is also needed to improve our 
understanding of the epidemiology of postinfectious 
cough, including patient age and ethnicity proﬁ les, 
environmental factors, and socioeconomic aspects.
Although postinfectious cough is typically described as 
being of 3–8 weeks’ duration,2,43 and pertussis can be 
clinically diagnosed in patients who have been coughing 
for 2 weeks or longer,44 our inclusion of patients with 
cough of 2–8 weeks’ duration without deﬁ nite infective 
signs might have increased clinical heterogeneity in our 
trial population. Some participants’ cough might have 
been due to asthma. However, if our sample had included 
a high proportion of these patients, we would have 
expected to see a signiﬁ cantly greater improvement in the 
montelukast group. We also adjusted for atopy in our 
analysis of LCQ total and domain score changes, overall 
cough severity, and paroxysmal cough severity. Participant-
reported wheeze associated with postinfectious cough at 
baseline would more likely have been virus-induced than 
asthma-related. Additionally, some participants might 
Panel: Research in context
Systematic review
We searched the Cochrane Library, Medline (for articles 
published from 1946 to week 31 of 2013), and Embase 
(for articles published from 1974 to week 31 of 2013) for 
randomised controlled trials and systematic reviews of 
leukotriene receptor antagonists for the treatment of 
postinfectious cough. The main search terms used were 
“persistent cough”, “prolonged cough”, “postinfectious cough”, 
“post-infectious cough”, “chronic cough”, “montelukast”, 
“Singulair”, “zaﬁ rlukast”, “Accolate”, “pranlukast”, “Onon”, 
“Azlaire”, and “leukotriene receptor antagonist*”. No language 
restrictions were applied to our search. Our search did not ﬁ nd 
any randomised placebo-controlled trials of leukotriene 
receptor antagonists for the treatment of postinfectious cough. 
A Cochrane review of symptomatic treatments for cough due 
to whooping cough also found no randomised controlled trials 
of leukotriene receptor antagonists.20
Interpretation
This study is the ﬁ rst double-blind randomised placebo-
controlled trial of montelukast for the treatment of 
postinfectious cough in adults. Montelukast was not 
associated with greater improvement in cough-speciﬁ c 
quality of life than placebo after 2 or 4 weeks. To identify 
future potential antitussive treatments, improved 
understanding is needed of the timecourse and underlying 
mechanisms of postinfectious cough.
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have misinterpreted the term “wheeze”. This issue is a 
well known limitation of patient-completed questionnaire 
items used to ascertain the presence of wheeze.45,46 A large 
observational study has previously shown that gastro-
oesophageal reﬂ ux is not an important cause of subacute 
cough in non-smoking adults.43
In conclusion, montelukast is not an eﬀ ective treatment 
for postinfectious cough. However, the burden of 
postinfectious cough in primary care makes it an ideal 
setting for future trials. To identify potential antitussive 
treatments, improved understanding is needed of the 
underlying mechanisms of postinfectious cough.
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